[HTML][HTML] Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma
MR Bishop, M Dickinson, D Purtill… - … England Journal of …, 2022 - Mass Medical Soc
Background Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
MR Bishop, M Dickinson, D Purtill… - New England …, 2022 - kyushu-u.elsevierpure.com
BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas
not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is …
not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is …
[引用][C] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro… - 2021 - lilloa.univ-lille.fr
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. Toggle
navigation English français Aide | Contact | À Propos | Ouvrir une session Portail HAL | Pages …
navigation English français Aide | Contact | À Propos | Ouvrir une session Portail HAL | Pages …
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
MR Bishop, M Dickinson, D Purtill, P Barba… - NEW ENGLAND …, 2022 - pure.pmu.ac.at
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma — PMU
Research Portal Skip to main navigation Skip to search Skip to main content PMU Research …
Research Portal Skip to main navigation Skip to search Skip to main content PMU Research …
[引用][C] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
MR Bishop, M Dickinson, D Purtill… - New England …, 2022 - produccioncientifica.ucm.es
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
MR Bishop, M Dickinson, D Purtill, P Barba… - NEW ENGLAND …, 2022 - iris.hunimed.eu
Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding
to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 …
to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 …
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
MR Bishop, M Dickinson… - New England …, 2022 - mdanderson.elsevierpure.com
BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas
not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is …
not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is …
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
MR Bishop, M Dickinson… - New England …, 2022 - researchinformation.amsterdamumc …
BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas
not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is …
not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is …
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
MR Bishop, M Dickinson, D Purtill… - New England …, 2021 - epub.ub.uni-muenchen.de
BACKGROUND Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas
not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is …
not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is …
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
MR Bishop, M Dickinson, D Purtill, P Barba… - The New England …, 2021 - europepmc.org
Background Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …
